Kornimate/medical-research-clean huggingface dataset:
cardiovascular disease cohort in guangdong province

Conditions: Cardiovascular Disease

Summary: patients with cardiovascular diseases from guangdong province will be recruited and followed up for at least 4 years to evaluate the risk factors for cardiovascular-related mortality and disability. physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of all-cause and cardiovascular mortality will be investigated during follow-up.

5,000 patients (30-85 years old) with primary hypertension, coronary heart disease, heart failure or peripheral vascular disease and who have been living in guangdong province for more than 5 years will be recruited. all participants will be prospectively followed up for the incidence of all-cause and cardiovascular mortality. information about socio-demographic, diet, lifestyle, psychological status, medical history and current medication will be collected by questionnaires. physical examinations including height, weight, waist and hip circumferences, blood pressure, fat mass and vital capacity will be conducted.besides, blood, urine and fecal samples will be collected for further analysis. the associations between diet and lifestyle and risks for cardiovascular disease will be evaluated.

Eligibility criteria:
inclusion criteria: * cardiovascular disease patients (30-85 years old) who have been living in guangdong province for more than 5 years. * patients have been diagnosed with primary hypertension, coronary heart disease, heart failure or peripheral vascular disease, etc. exclusion criteria: * patients with cardiogenic (acute pericarditis, rheumatic coronary arteritis, hypertrophic cardiomyopathy, etc.) or non-cardiogenic chest pain. * any subject who suffer from malignant tumors, infectious diseases, advanced liver disease, major disability and cannot participate in the study.
a study to assess the effects of vildagliptin on gastric emptying in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes for at least 6 months * blood glucose criteria must be met * bmi in the range 22-40 exclusion criteria: * history of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes * use of thiazolidinediones or need for insulin within 3 months prior to screening * significant concomitant diseases or complications of diabetes * high fasting triglycerides as defined by the protocol other protocol-defined inclusion/exclusion criteria may apply

Keywords: vildagliptin type 2 diabetes
total body irradiation and cladribine before allogeneic hematopoietic cell transplantation in patients with aml (acute myeloid leukemia) and myelodysplastic syndromes

Conditions: Acute Myeloid Leukemia Myelodysplastic Syndromes

Summary: a single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with aml( acute myeloid leukemia) and myelodysplastic syndromes.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 60 years. 2. patient is a candidate for allogeneic hematopoietic cell transplantation due to acute myeloid leukemia(intermediate or high risk acute myeloid leukemia in complete remission, low risk with positive minimal residual disease) or high risk myelodysplastic syndrome. 3. demonstration of chemosensitivity in the case of treatment regimens with cladribine in induction therapy. 4. patient signed informed consent form prior to any study related screening procedures are performed. 5. patient has eastern cooperative oncology group performance status score of 0 or 1. 6. patient is a candidate for allogeneic hematopoietic cell transplantation from sibling or unrelated donor (full matched or 9/10 mismatched) or from haploidentical donor. exclusion criteria: 1. has received more than 1 allogeneic hematopoietic cell transplantation. 2. presence of active uncontrolled infection (i.e. sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection). 3. known active human immunodeficiency virus, hepatitis b virus or hepatitis c virus infection (positive polymerase chain reaction test) or risk of hepatitis b virus reactivation (hepatitis b surface antigen positive). 4. presence of active disease in acute myeloid leukemia patients. 5. history or current diagnosis for uncontrolled or significant cardiac or pulmonary disease. 6. presence of severe renal or liver dysfunction (creatinine, alanine aminotransferase,aspartate aminotransferase or bilirubin concentration \> 3.0 upper limit of normal 7. currently pregnancy or breast feeding. 8. treatment of any other investigational agent in the same time as this study. 9. known allergies, hypersensitivity, or intolerance to cladribine or similar compounds. 10. women of childbearing potential who do not agree to use two effective methods of contraception.
real-world study on the effectiveness and safety of control-iq technology in teenagers with type 1 diabetes engaging in regular physical activity

Conditions: Type 1 Diabetes Mellitus

Summary: we hypothesize that the use of the control-iq system positively influences glycemic control in teenagers with type 1 diabetes during physical activity. to test this hypothesis, we will evaluate the glucose profiles (based on cgm metrics) of adolescents engaging in different types, intensities, and durations of physical activity over a 14-day period, in real-life conditions. we will compare glucose control on exercise days with that on sedentary days. as a secondary objective, we will investigate the influence of factors such as anthropometric characteristics, type and duration of exercise, the use of the exercise mode and other management strategies used for physical activity, on glycemic outcomes. regarding the safety, we will report any episodes of severe hypoglycemia or diabetic ketoacidosis (dka). this is an observational, open-label, non-randomized, real-world study. each participant will be provided with a diary to record detailed information about physical activity sessions over a 14-day period, including type, intensity, and duration of exercise, and timing and composition of pre-exercise meals. clear instructions on how to complete the diary will be provided. cgm metrics will be analyzed throughout the 14-day observation period, including time in range, time in tight range, time above range, time below range, mean glucose level, and coefficient of variation. a daily comparison will be performed between metrics recorded on days of physical activity and sedentary days, assessing the entire day as well as daytime (07:00-23:00) and nighttime (23:00-07:00) periods. the influence of factors such as anthropometrics, type of physical activity, the use of the exercise mode and other specific management strategies, type and duration of exercise, and pre-exercise meals on cgm metrics will be evaluated. the frequency of severe hypoglycemia and dka episodes, as defined by international guidelines, will be assessed.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 diabetes according to international society for pediatric and adolescent diabetes (ispad) guidelines * duration of diabetes \> 12 months * age \< 20 years * pubertal development completed according to the tanner stage * use of control-iq technology for at least 3 months * automatic mode use for at least 70% of the time during the 2 weeks preceding enrollment * cgm use for at least 70% of the time during the 2 weeks preceding enrollment * regular physical activity (at least 2 sessions per week, each lasting at least 45 minutes) exclusion criteria: * uncontrolled celiac disease or thyroid disease * presence of other chronic illnesses * psychiatric or neurological conditions, including eating disorders, that may interfere with the study * chronic use of medications (other than insulin) that may affect glucose control * chronic use of substances or drugs that could impact cgm accuracy

Keywords: type 1 diabetes pediatric diabetes sport physical activity automated insulin delivery
"effects of manual lymphatic drainage in the neck in healthy subjects. experimental randomized crossover study"

Conditions: Blood Pressure; Nervous System Diseases, Sympathetic; Heart Rate Low; Lymphatic Diseases

Summary: drainage manoeuvres described in different manual lymphatic drainage methods, suggest modificactions in vital signs, by changes at nervous system, that would involve modifications to heart rate, breathing rate, blood pressure, cardiac vascular level (arteries and lymphatics). in addition this hypothetical relaxing effect could be beneficial for other types of pathologies associated with the presence of stress, cardiac problems, respiratory pathology, muscle tension, muscle trigger points, etc. with this study investigators compare different manoeuvres in the neck area to observe the results in the participants regarding the basal state.

differentes drainage manoeuvres suggest changes at nervous system (sympathetic and parasympathetic nervous system) and other vital constants

Eligibility criteria:
inclusion criteria: * healthy men and women, physiotherapy students, to accept voluntarily participate and sign informed consent exclusion criteria: * systemic diseases, trauma history, neurological diseases, subjects with chronic pain, cardiovascular history of importance, depression, individuals who know the technique of mld or that are under any medical treatment.
the effects of remote organ ischemic preconditioning on systemic inflammatory and glycocalyx integrity parameters

Conditions: Remote Organ Ischemic Preconditioning

Summary: ischemia-reperfusion (ir) injury during liver transplantation is one of the major causes of mortality and morbidity associated with transplantation. remote organ ischemic preconditioning (ripc) is one of the most investigated practices to reduce ir injury. in this study, for the first time in the clinic, the effect of ripc will be evaluated via both systemic inflammation parameters and also parameters showing glycocalyx integrity, on living-donor liver recipients.


Eligibility criteria:
inclusion criteria: * patients followed up by acıbadem hospital organ transplantation center * patients accepted to participate in the study * older than 18 years of age * asa class iii * meld score \>12 * scheduled for elective liver transplantation surgery from a living donor exclusion criteria: * patients undergoing re-transplantation * under the age of 18 years * patients undergoing emergency surgery * patients with hepatorenal or hepatopulmonary syndrome * patients receiving mechanical ventilation support in the icu * patients refusing to participate

Keywords: remote organ ischemic preconditioning ischemia reperfusion injury glycocalyx integrity parameters systemic inflammation parameters
omega-3 on lipid profile and serum leptin level n neonates with intrauterine growth restriction

Conditions: Lipid Profile; Neonates; Intrauterine Growth Restriction

Summary: the aim of our study will demonstrate the effect of omega 3 supplementation on serum lipid profile level and leptin level in neonates with intrauterine growth restriction( iugr)

intrauterine growth restriction is a major cause of perinatal mortality and morbidity . it is noted to affect approximately 5-15 % of pregnant women. egypt has one of the highest incidences of intrauterine growth restriction. the incidence of iugr varies among countries, populations, races and increases with decreasing gestational age. 14 to 20 million infants have been affected with intrauterine growth restriction cases in the developing countries annually. a complex and dynamic interaction of maternal, placental and fetal environment is involved in ensuring normal fetal growth. an imbalance or lack of coordination in this complex system may lead to intrauterine growth restriction. intrauterine growth restriction( iugr) results in significant perinatal and long-term complications, including increased neonatal mortality and morbidity and higher risk for developing metabolic syndrome later in life. physiological differences have been noted in growth restricted infants. intrauterine amino acid disturbances similar to biochemical changes seen in postnatal protein deprived states have been detected. protein metabolism defect and altered lipid metabolism also have been described. undernourishment in utero appears to be associated with persisting changes in the metabolic functions. birth weight influences the lipoprotein profile and cholesteryl ester transfer protein, which promotes a proatherogenic lipoprotein profile in plasma by determining chemical, physical and biological properties of the respective lipoprotein particle in neonates. recent research suggests that several of major disease of later life, including coronary heart disease, hypertension \& type ii diabetes originate in impaired intrauterine growth and development. these diseases may be consequence of programming whereby a stimulus or insult at a critical, sensitive period of early life has a permanent effect on structure, physiology and metabolism.

Eligibility criteria:
inclusion criteria: * any full-term intrauterine growth restriction (iugr) neonate exclusion criteria: * preterm neonates * who died before feeding was established * multiple congenital anomalies including git anomalies * congenital infection * cholestasis * infant of diabetic mother (idm)
rhinogenic headache improvement after nasal operation

Conditions: Headache

Summary: objective: to determine the efficacy of surgical correction of intranasal mucosal contact points in improving quality of life and decreasing medication use in patients with rhinogenic headaches.

significance: chronic, debilitating headaches that resist maximal medical treatment by various headache specialists are sometimes linked to structural anomalies within the nose that exert pressure on apposing mucosal surfaces. a number of otolaryngologists have reported success in alleviating rhinogenic headaches with contact point correction surgery. this practice is supported by anecdotal reports along with retrospective and observational studies; however, a prospective study with an appropriate surgical control group has not been conducted. because the specific effect of contact point correction has not yet been differentiated from the placebo effect of surgery itself, many headache specialists are reluctant to recommend surgical evaluation for their patients. to demonstrate the efficacy of contact point correction surgery to both the headache and otolaryngology communities - and thus, to make this treatment option more widely available to rhinogenic headache sufferers - a randomized controlled trial is needed.

Eligibility criteria:
inclusion criteria: * chronic (\> 2 months) pain or pressure over nasal bridge, glabella, or forehead * unilateral or bilateral nasal septal deviation that is chronically symptomatic (e.g. nasal airway obstruction) * failure of standard medical therapy for headache * symptomatic contact points as demonstrated by physical examination, sinus ct and nasal endoscopy * relief of headache after application of topical anesthetic to contact points * contact points that remain after mucosal decongestion * absence of any other obvious cause of headaches after a thorough evaluation by a neurologist, ophthalmologist, dentist, internist, or other related specialist exclusion criteria: * previous sinonasal surgery * active acute sinonasal disease: 1. seasonal allergic exacerbations with mucosal swelling 2. acute infectious rhino-sinusitis * chronic sinonasal problems: 1. severe nasal polyps mimicking contact points 2. mucoceles protruding from sinuses into nasal cavity 3. nasal and sinus tumors * general medical condition that precludes elective surgery (including pregnancy)

Keywords: headache rhinogenic nose nasal septum deviated septum surgery septoplasty turbinoplasty contact point hit-6
a study to assess the safety and tolerability of bms-986158 alone and in combination with either ruxolitinib or fedratinib in participants with blood cancer (myelofibrosis)

Conditions: Myelofibrosis

Summary: the purpose of this study is to assess the safety, tolerability, and efficacy of bms-986158 alone and in combination with either ruxolitinib or fedratinib in participants with dynamic international prognostic scoring system (dipss)-intermediate or high risk blood cancer. part 1 consists of bms-986158 in combination with either ruxolitinib or fedratinib and part 2 consists of bms-986158 in combination with either ruxolitinib or fedratinib and bms-986158 alone.


Eligibility criteria:
inclusion criteria: * diagnosis of primary myelofibrosis (pmf), post-essential thrombocythemia (et) or post-polycythemia vera (pv) myelofibrosis * treatment-related toxicities from prior therapy resolved to grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment * must agree to follow specific methods of contraception, if applicable exclusion criteria: * women who are pregnant or breastfeeding at screening * any significant acute or uncontrolled chronic medical illness other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986158 fedratinib myelofibrosis ruxolitinib
titrating-dose of lonafarnib in combination with ritonavir

Conditions: Chronic Delta Hepatitis

Summary: a phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (hdv)

this is a phase 2 study of 24 weeks of treatment with a dose-titration regimen of lonafarnib/ritonavir in up to 15 patients chronically infected with hdv: lonafarnib starting at 50 mg twice daily (bid) in combination with ritonavir 100 mg bid and escalating lonafarnib as tolerated. the duration of the study for each patient is approximately 13 months (up to 4 weeks for screening, 24 weeks of treatment, 4 weeks for the primary follow-up visit, and monthly safety follow-up visits for 5 months thereafter). the 6-month follow-up after the last dose of study drug is designed to allow evaluation of the clinical and virologic course after completion of the 24-week treatment period.

Eligibility criteria:
key inclusion criteria: 1. male or female, 18 to 65 years of age, inclusive 2. chronic hdv infection documented by a positive hdv antibody (ab) test of at least 6 months duration and detectable hdv ribonucleic acid (rna) by quantitative polymerase chain reaction (qpcr) at study entry 3. liver biopsy demonstrating evidence of chronic hepatitis 4. willingness to practice appropriate contraception key exclusion criteria: 1. previous use of lonafarnib 2. co-infected with human immunodeficiency virus (hiv) or hepatitis c virus (hcv) 3. active jaundice defined by total bilirubin level \>2.0 mg/dl and known not to have gilbert's disease 4. decompensated liver disease or cirrhosis, history of bleeding esophageal varices, ascites, or hepatic encephalopathy 5. serum creatinine concentration ≥1.5 times upper limit of normal (uln) 6. evidence of another form of viral hepatitis (not including hepatitis b virus or hcv) or another form of liver disease 7. evidence of hepatocellular carcinoma 8. use of alfa interferon, either interferon alfa-2a or interferon alfa-2b, or peginterferon alfa-2a within 2 months before the start of screening 9. concomitant use of any of the following: 1. medications or foods that are known moderate or strong inducers or inhibitors of cyp3a4 or cyp2c19 2. drugs known to prolong the pr interval or qt interval of the electrocardiogram 3. receipt of systemic immunosuppressive therapy within the 3 months before start of screening 4. statins, due to inhibition of mevalonate synthesis, which reduces protein prenylation 5. medications contraindicated in the prescribing information for ritonavir
innovative care pathway in physical activity and behavior change in coronary patients post-cardiac rehabilitation

Conditions: Individualised Physical Activity Program; Coronary Patient

Summary: the objective of this 18-month research is to show the effectiveness of an individualized physical activity( pa) compared to standard pa management and voluntary pa, to achieve a change in the behavior of the coronary patient.


Eligibility criteria:
inclusion criteria: * post-infarction coronary artery patient aged 18 years and older, with no gender difference. * patients engaged in a follow-up care and cardiovascular rehabilitation program at the supervaltech center. * patient at low to moderate rare risk of complication (rare score 2 to 3) * patients equipped with smartphones, laptops or other equipment compatible with downloading an application with their personal id * patient able to understand french for the purpose of conducting the study. * affiliated member or beneficiary of a social security scheme. * participant who has been informed and has given free, informed and written consent (no later than the day of inclusion and before any examination required by the research). exclusion criteria: * patients with a formal contraindication to physical activity such as: unstabilized coronary syndrome, decompensated heart failure, severe ventricular arrhythmias, intracardiac thrombus at risk embolic, pah, moderate pericardial effusion, history of thrombophlebitis with or without pulmonary embolism, severe and/or symptomatic left ventricular ejection obstruction. * patients with ongoing infectious disease * participant whose physical and/or psychological health is severely impaired, which in the opinion of the investigator may affect the study participant's compliance. * participant included in other research * participant in a period of exclusion from another research still in progress at the time of inclusion. * protected participant: an adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision. * pregnant, breastfeeding or parturient women. * participant hospitalized without consent.

Keywords: cardiac rehabilitation ischemic heart disease physical activity wearables